Form 4: Vaxcyte CEO Grant Pickering Exercises Stock Options, Reports Beneficial Ownership Changes

Vaxcyte's CEO, Grant Pickering, executed stock options at prices of $5.35 and $20.93, altering his beneficial ownership in the company.

Summary

• On April 4, 2025, Grant Pickering, the CEO of Vaxcyte, Inc., exercised stock options to purchase 15,781 shares at $5.35 and 4,752 shares at $20.93.
• These transactions increased his direct ownership to 514,023 shares after the $5.35 exercise and 518,775 shares after the $20.93 exercise.
• Pickering also indirectly owns 136,215 shares through a children's trust for his daughter and another 136,215 shares through a children's trust for his son.
• Following these transactions, Pickering directly holds 186,936 stock options exercisable at $5.35 and 298,360 stock options exercisable at $20.93.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option exercises. The CEO exercising options can be seen as a mild positive, but it's not a strong indicator.

Positives

• The exercise of stock options by the CEO could be interpreted as a positive signal, indicating his confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry where stock options are frequently used as incentives.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the CEO's increased stake in the company.

Key Dates

Keywords

Vaxcyte, Grant Pickering, stock options, beneficial ownership, Form 4, securities, CEO